Novartis AG ADR (NVS)vsEverpure, Inc. (P)
NVS
Novartis AG ADR
$144.62
-1.33%
HEALTHCARE · Cap: $275.95B
P
Everpure, Inc.
$74.63
+2.58%
TECHNOLOGY · Cap: $23.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1445% more annual revenue ($56.58B vs $3.66B). NVS leads profitability with a 23.9% profit margin vs 5.1%. P appears more attractively valued with a PEG of 1.61. P earns a higher WallStSmart Score of 55/100 (C-).
NVS
Buy51
out of 100
Grade: C-
P
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.0%
Fair Value
$109.95
Current Price
$144.62
$34.67 premium
Intrinsic value data unavailable for P.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Earnings expanding 139.7% YoY
Revenue surging 20.4% year-over-year
Areas to Watch
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Expensive relative to growth rate
Trading at 17.0x book value
5.1% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : P
The strongest argument for P centers on EPS Growth, Revenue Growth. Revenue growth of 20.4% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Bear Case : P
The primary concerns for P are PEG Ratio, Price/Book, Profit Margin. A P/E of 130.2x leaves little room for execution misses.
Key Dynamics to Monitor
NVS profiles as a declining stock while P is a growth play — different risk/reward profiles.
P carries more volatility with a beta of 1.44 — expect wider price swings.
P is growing revenue faster at 20.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
P scores higher overall (55/100 vs 51/100) and 20.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Everpure, Inc.
TECHNOLOGY · COMPUTER HARDWARE · USA
Pandora Media, Inc. provides music discovery platform services in the United States and internationally. The company is headquartered in Oakland, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?